RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, has announced the repurchase of 52,865 ordinary shares at a price of $2.39 per share, executed on 4 November 2026. The bought-back shares will be held in treasury and will carry no voting rights, reducing the total voting rights in the company to 319,205,347. The buyback was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) is an LSE-listed investment fund managed by RTW Investments, LP
  • The company repurchased 52,865 ordinary shares at $2.39 per share on 4 November 2026, with shares to be held in treasury
  • Total issued ordinary share capital stands at 345,967,440, with 26,762,093 shares now held in treasury; total voting rights are 319,205,347
  • Investors should watch whether further buybacks are conducted ahead of the next AGM authority expected in 2027

Treasury Placement Leaves 26,762,093 RTWG Shares Without Voting Rights

Following settlement of the 4 November 2026 repurchase, RTW Biotech Opportunities Ltd's total issued ordinary share capital stands at 345,967,440 shares. Of these, 26,762,093 ordinary shares are now held in treasury and attract no voting rights under applicable rules. The resulting total voting rights figure of 319,205,347 is the denominator shareholders must use when calculating whether they are required to notify their interest, or any change to their interest, under the FCA's Disclosure and Transparency Rules. The company stated it is its current intention to continue holding any repurchased shares in treasury rather than cancelling them.

June 2026 AGM Authority Permits Repurchase of Up to 14.99% of Ordinary Shares

The buyback programme operates under authority granted by shareholders at RTW Biotech Opportunities Ltd's Annual General Meeting in June 2026. That authority permits the company to repurchase a maximum of 14.99% of its ordinary shares. The announcement notes that the actual number of shares repurchased will depend on prevailing market conditions. The authority remains in force until a new shareholder mandate is granted — expected at the 2027 Annual General Meeting — or until it is expressly revoked by shareholders. The company has confirmed that it cannot pay a price that would equate to a premium to net asset value for any repurchased shares.

Jefferies International Acts as Broker for RTWG's Ongoing Buyback Transactions

RTW Biotech Opportunities Ltd has instructed Jefferies International Limited as its broker for buyback transactions, an arrangement the company states is in accordance with FCA Listing Rules and its general authority to repurchase shares. Contact points listed for investor enquiries include RTW Investments, LP — the fund's investment manager — alongside Jefferies representatives Gaudi Le Roux and Harry Randall-Knowles. RTW Investments, LP is described in the announcement as a healthcare-focused entrepreneurial investment firm with deep scientific expertise and a track record of supporting companies developing life-changing therapies across biopharmaceutical and medical technology sectors.